Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Favors Predictability Over Speed In Next Round Of MDUFMA

This article was originally published in The Gray Sheet

Executive Summary

Senior device industry staffers are more interested in improving the predictability of FDA's premarket review process than pushing the agency to accelerate its performance, an FDA 1report suggests
Advertisement

Related Content

Survey Suggests Industry Aversion To Facility Registration Fee
Survey Suggests Industry Aversion To Facility Registration Fee
MDUFMA Reauthorization Agreement Is In Place – AdvaMed
MDUFMA Reauthorization Agreement Is In Place – AdvaMed
FDA On Track With MDUFMA Review Goals, Report Shows
FDA Will Not Meet Proposed PMA Review Goal; Industry Expresses Frustration
MDUFMA II Should Address Pre-IDE Process, Cycle Goals – Stakeholders
AdvaMed President Ubl Sets Ambitious FDA Performance, International Goals
AdvaMed President Ubl Sets Ambitious FDA Performance, International Goals
Funding Limits Will Force Choices At Device Evaluation Office – Tillman
Advertisement
UsernamePublicRestriction

Register

MT023499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel